CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE II CLINICAL TRIAL OF SYH2070 INJECTION FOR THE TREATMENT OF MIXED HYPERLIPIDAEMIA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase II clinical trial of SYH2070 Injection (the "**Product**") developed by the Group for the treatment of mixed hyperlipidaemia has been officially initiated at the first centre in China.

Existing therapeutic regimens for mixed hyperlipidaemia require the combined administration of multiple medicines. Currently, there remains an unmet clinical need for treatments that can simultaneously reduce triglycerides ("**TG**") and low-density lipoprotein cholesterol ("**LDL-C**"). The Product is an N-acetylgalactosamine (GalNAc)-conjugated small interfering ribonucleic acid (siRNA) drug independently developed by the Group, targeting the angiopoietin-like 3 ("**ANGPTL3**") messenger ribonucleic acid ("**mRNA**") in hepatocytes. The Product can persistently and specifically silence ANGPTL3 mRNA and suppress the expression of ANGPTL3 protein, thereby enhancing lipoprotein lipase (LPL) activity and inhibiting endothelial lipase (EL) activity. This reduces the conversion of very low-density lipoprotein (VLDL) to low-density lipoprotein (LDL), achieving the goal of simultaneously, persistently, stably lowering TG and LDL-C, while significantly improving patient adherence through a longer dosing interval.

Previously, the Group obtained the Notice of Approval for Clinical Trial of Drug (Acceptance No.: 2025LP02566) from the National Medical Products Administration of the People's Republic of China in September 2025, and has completed the Phase I clinical trial and initiated this Phase II clinical trial. This Phase II clinical trial is designed to evaluate the efficacy, safety, pharmacokinetic (PK) profiles, and immunogenicity of the Product relative to placebo in subjects with mixed hyperlipidaemia receiving lipid-lowering treatment, with a planned enrolment of 240 subjects. Currently, subject recruitment and screening are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 7 July 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.